{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-25-000048","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2025-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.940884+00:00","generated_at":"2026-05-23T02:05:28.940350+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xencor reports positive interim Phase 1 results for XmAb942; half-life >71 days","bullets":["XmAb942 well tolerated; no serious AEs, no discontinuations.","Half-life >71 days supports 12-week maintenance dosing in planned Phase 2b UC study.","Phase 2b XENITH-UC trial in moderate-to-severely active UC expected to start H2 2025 (n~220).","TL1A x IL23p19 bispecific lead selection on track; FIH study planned for 2026.","Company to host call at 5pm ET today."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-25-000048","json":"https://secwatch.observer/filing/0001326732-25-000048.json","markdown":"https://secwatch.observer/filing/0001326732-25-000048.md","text":"https://secwatch.observer/filing/0001326732-25-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673225000048/0001326732-25-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673225000048/xncr-20250429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T02:05:28.940350+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}